Summit Therapeutics (SMMT) Shares Outstanding (2017 - 2026)

Summit Therapeutics' Shares Outstanding (Entity) history runs 10 years deep, the most recent figure standing at $776.0 million for Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 4.64% year-over-year to $776.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $776.0 million (up 4.64% YoY) and the FY2025 annual result came in at $775.4 million, up 5.12% from the prior year.
• Shares Outstanding (Entity) was $776.0 million for Q1 2026 at Summit Therapeutics, roughly flat from $775.4 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $776.0 million in Q1 2026 and bottomed at $98.1 million in Q1 2022.
• A 5-year average of $571.3 million and a median of $702.0 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) gained 0.79% — and 2023, when it soared 611.04%.
• Summit Therapeutics' Shares Outstanding (Entity) stood at $211.1 million in 2022, then surged by 232.4% to $701.7 million in 2023, then advanced by 5.13% to $737.6 million in 2024, then climbed by 5.12% to $775.4 million in 2025, then rose by 0.08% to $776.0 million in 2026.
• Business Quant data shows SMMT's Shares Outstanding (Entity) at $776.0 million in Q1 2026, $775.4 million in Q4 2025, and $744.4 million in Q3 2025.